Medical Excellence Capital

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

GC Therapeutics is a biotechnology company focused on the programming of patient-derived stem cells into various cell types using synthetic biology. The company has developed a proprietary platform that integrates synthetic biology and artificial intelligence, allowing for efficient and scalable cell programming. Their technology enables the creation of customized cells, known as SuperCells™, tailored for specific medical conditions. With a foundation rooted in research from Professor George Church's lab at Harvard Medical School, GC Therapeutics aims to streamline the manufacturing process of unique cell therapies while enhancing cell quality and efficiency. The company is composed of a team of biologists and tissue engineers committed to advancing this innovative approach to improve patient outcomes.

Truvian Sciences Inc. is a diagnostic company based in San Diego, California, focused on revolutionizing the blood testing industry. Incorporated in 2015, the company has developed an automated benchtop system that delivers lab-accurate results for a variety of health tests. Its comprehensive wellness panel includes commonly ordered routine blood tests such as complete blood count, metabolic panel, and lipid panel, all from a single sample. Additionally, Truvian's software system enables healthcare practitioners to efficiently deliver test results to patients through a user-friendly platform.

ProJenX is a clinical-stage biopharmaceutical company founded in 2021 and based in Nissequogue, New York. The company focuses on developing innovative small molecule therapeutics aimed at treating Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. ProJenX's lead therapeutic candidate specifically targets motor neuron degenerative pathways by blocking MAP4 kinases, which has shown promise in various laboratory models of ALS. This oral, brain-penetrant small molecule aims to address endoplasmic reticulum stress-related motor neuron loss, offering potential new treatment options for patients suffering from these debilitating conditions.

Avilar Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative extracellular protein degraders, representing a new approach in targeted protein degradation. The company has created an integrated discovery platform aimed at extending protein degradation beyond intracellular proteins. Avilar's novel degraders function by binding to disease-causing proteins in circulation and transporting them to the hepatocyte endolysosome, where these unwanted proteins are degraded. This mechanism offers potential therapeutic solutions for the treatment of serious diseases, positioning Avilar Therapeutics at the forefront of advancing medical treatments through targeted protein management.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

ProJenX is a clinical-stage biopharmaceutical company founded in 2021 and based in Nissequogue, New York. The company focuses on developing innovative small molecule therapeutics aimed at treating Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. ProJenX's lead therapeutic candidate specifically targets motor neuron degenerative pathways by blocking MAP4 kinases, which has shown promise in various laboratory models of ALS. This oral, brain-penetrant small molecule aims to address endoplasmic reticulum stress-related motor neuron loss, offering potential new treatment options for patients suffering from these debilitating conditions.

Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.